Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (51-60 of 283) with videos related to

Pageof 29
Sort By:
Blood|October 1, 2008
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13Todd A Fehniger, John C Byrd, Guido Marcucci, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 26, 2016
Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center ReviewArmin Rashidi, John F DiPersio, Peter Westervelt, et al.
Journal of the American Geriatrics Society|December 15, 2018
Geriatric Assessment in Older Adults with Multiple MyelomaTanya M Wildes, Sascha A Tuchman, Heidi D Klepin, et al.
Annals of Hematology|April 21, 2025
Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trialsMeletios Dimopoulos, Kazutaka Sunami, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2015
Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple MyelomaPierre Squifflet, Stefan Michiels, David Siegel, et al.
Leukemia & Lymphoma|February 5, 2015
Socioeconomic status is independently associated with overall survival in patients with multiple myelomaMark A Fiala, Joseph D Finney, Jingxia Liu, et al.
Leukemia & Lymphoma|June 18, 2021
A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myelomaLawrence Liu, Mark Fiala, Feng Gao, et al.
Bone Marrow Transplantation|August 30, 2019
Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myelomaMark A Fiala, Venkata Vosuri, Scott Goldsmith, et al.
Annals of Hematology|September 3, 2024
A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myelomaScott R Goldsmith, Michael J Slade, Mark Fiala, et al.
Clinical Lymphoma & Myeloma|January 12, 2008
Bortezomib inhibits osteoclast activity in patients with multiple myelomaGeoffrey L Uy, Rachna Trivedi, Shachar Peles, et al.
Pageof 29

Showing results (51-60 of 283) with videos related to

Sort By:
Pageof 29
Blood|October 1, 2008
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13Todd A Fehniger, John C Byrd, Guido Marcucci, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 26, 2016
Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center ReviewArmin Rashidi, John F DiPersio, Peter Westervelt, et al.
Journal of the American Geriatrics Society|December 15, 2018
Geriatric Assessment in Older Adults with Multiple MyelomaTanya M Wildes, Sascha A Tuchman, Heidi D Klepin, et al.
Annals of Hematology|April 21, 2025
Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trialsMeletios Dimopoulos, Kazutaka Sunami, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2015
Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple MyelomaPierre Squifflet, Stefan Michiels, David Siegel, et al.
Leukemia & Lymphoma|February 5, 2015
Socioeconomic status is independently associated with overall survival in patients with multiple myelomaMark A Fiala, Joseph D Finney, Jingxia Liu, et al.
Leukemia & Lymphoma|June 18, 2021
A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myelomaLawrence Liu, Mark Fiala, Feng Gao, et al.
Bone Marrow Transplantation|August 30, 2019
Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myelomaMark A Fiala, Venkata Vosuri, Scott Goldsmith, et al.
Annals of Hematology|September 3, 2024
A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myelomaScott R Goldsmith, Michael J Slade, Mark Fiala, et al.
Clinical Lymphoma & Myeloma|January 12, 2008
Bortezomib inhibits osteoclast activity in patients with multiple myelomaGeoffrey L Uy, Rachna Trivedi, Shachar Peles, et al.
Pageof 29